BRCA1-deficient breast cancers with PTEN mutation generally had higher T cell-inflamed signature scores compared to BRCA1-proficient breast cancers and BRCA1-deficient breast cancers without PTEN mutation (Fig 4F). This evidence concerns the gene BRCA1 and breast cancer.